Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines

Research output: Contribution to journalReviewpeer-review

  1. ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma

    Research output: Contribution to journalEditorialpeer-review

  2. Daily Adaptive Proton Therapy: Is it Appropriate to Use Analytical Dose Calculations for Plan Adaption?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Feasibility of Implementing Deep Inspiration Breath-Hold for Pediatric Radiation Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Andrew Wirth
  • N George Mikhaeel
  • Berthe M P Aleman
  • Chelsea C Pinnix
  • Louis S Constine
  • Umberto Ricardi
  • Tim M Illidge
  • Hans Theodor Eich
  • Bradford S Hoppe
  • Bouthaina Dabaja
  • Andrea K Ng
  • Youlia Kirova
  • Anne Kiil Berthelsen
  • Karin Dieckmann
  • Joachim Yahalom
  • Lena Specht
View graph of relations

Involved node radiation therapy for lymphoma was introduced with the aim of using the smallest effective treatment volume, individualized to the patient's disease distribution, to avoid the potentially unnecessary normal tissue exposure and toxicity risks associated with traditional involved field radiation therapy. The successful implementation of involved node radiation therapy requires optimal imaging and precise coregistration of baseline imaging with the radiation therapy planning computed tomography scan. Limitations of baseline imaging, changes in patient position, and anatomic changes after chemotherapy may make this difficult in routine practice. Involved site radiation therapy (ISRT) was introduced by the International Lymphoma Radiation Oncology Group as a slightly larger treated volume, intended to allow for commonly encountered uncertainties. In addition to imaging considerations, the optimal ISRT treatment volume also depends on disease histology, stage, nodal or extranodal location, and the type and efficacy of systemic therapy, which in turn influence the distribution of macroscopic and potential subclinical disease. This article presents a systematic overview of ISRT, updating key evidence and highlighting differences in the application of ISRT across the lymphoma clinical spectrum.

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number5
Pages (from-to)909-933
Number of pages25
Publication statusPublished - 1 Aug 2020

ID: 61016404